Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021;237(1):46-55.
doi: 10.1159/000504841. Epub 2020 Jan 21.

Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry

Kristina Callis Duffin  1 , Marc A Mason  2 , Kenneth Gordon  3 , Ryan W Harrison  2 , Margaux M Crabtree  2 , Adriana Guana  4 , Rebecca Germino  4 , Mark Lebwohl  5
Affiliations
Observational Study

Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry

Kristina Callis Duffin et al. Dermatology. 2021.

Abstract

Background: Real-world studies evaluating patients with challenging-to-treat localizations of psoriasis (scalp, nail, and palmoplantar) are limited.

Objective: To characterize patients with versus without psoriasis in challenging-to-treat areas seen in routine US clinical practice.

Methods: This retrospective observational study included all adult patients with psoriasis enrolled in the Corrona Psoriasis Registry between April 2015 and May 2018 who initiated a biologic therapy at registry enrollment. Patients were stratified by the presence of scalp, nail, or palmoplantar psoriasis (nonmutually exclusive groups). Patient demographics, clinical char-acteristics, disease activity, and patient-reported outcome measures (pain, fatigue, itch, EuroQol visual analog scale [EQ VAS], Dermatology Life Quality Index [DLQI], and Work Productivity and Activity Impairment questionnaire [WPAI]) were assessed at registry enrollment and compared between patients with versus without each challenging-to-treat area using nonparametric Kruskal-Wallis tests for continuous variables and χ2 or Fisher exact tests for categorical variables. Generalized linear regression models were used to estimate differences in disease activity and patient-reported outcomes between patients with versus without each challenging-to-treat area.

Results: Among 2,042 patients with psoriasis (mean age [±SD], 49.6 ± 14.7 years; 51.5% male), 38.4% had psoriatic arthritis (PsA), 38.1% had scalp psoriasis, 16.0% had nail psoriasis, 10.9% had palmoplantar psoriasis, and 26.2% had a combination of ≥2 challenging-to-treat areas and PsA; only 34.2% had body plaque psoriasis without PsA or challenging-to-treat areas. Patients in all challenging-to-treat groups reported higher (mean [95% CI]) itch (scalp, 58.01 [57.62-58.40] vs. 54.35 [53.99-54.72]; nail, 56.42 [56.02-56.81] vs. 55.59 [55.20-55.97]; palmoplantar, 60.22 [59.86-60.59] vs. 55.15 [54.79-55.54]) and lower EQ VAS (scalp, 68.12 [67.78-68.48] vs. 69.46 [69.12-69.81]; nail, 66.21 [65.89-66.55] vs. 69.48 [69.14-69.83]; palmoplantar, 66.21 [66.07-66.75] vs. 69.29 [68.94-69.94]) scores than those without the respective challenging-to-treat localization. Patients with nail or palmoplantar psoriasis reported higher pain, fatigue, and DLQI scores than those without. Higher proportions of patients with scalp or palmoplantar psoriasis reported work impairment compared with those without.

Conclusion: Two-thirds of patients with psoriasis who initiated biologic therapy had PsA and/or ≥1 challenging-to-treat area. Patients with challenging-to-treat areas had worse patient-reported outcome scores than those without, indicating a significant burden of challenging-to-treat areas on patients' quality of life.

Keywords: Psoriasis; Quality of life; Real-world evidence; Registry.

PubMed Disclaimer

Conflict of interest statement

K.C.D. is an investigator and consultant for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol-Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, and UCB. M.A.M., R.W.H., and M.M.C. are employees of Corrona, LLC. K.G. is an investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, and Janssen and a consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Janssen, Novartis, and Pfizer. A.G. and R.G. were employees of Novartis Pharmaceuticals Corporation at the time of this study. M.L. is an employee of Icahn School of Medicine at Mount Sinai, which receives research funds from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen/Johnson & Johnson, Kadmon, MedImmune/AstraZeneca, Novartis, Pfizer, Valeant, and Vidac and is also a consultant for Allergan, Aqua, Corrona, LEO Pharma, and Promius.

Figures

Fig. 1
Fig. 1
Flowchart of Patients and Methods. BSA, body surface area; CTT, challenging to treat; DLQI, Dermatology Life Quality Index; EQ VAS, EuroQol visual analog scale; IGA, Investigator's Global Assessment; PROs, patient-reported outcomes; US FDA, United States Food and Drug Administration; WPAI, Work Productivity and Activity Impairment.
Fig. 2
Fig. 2
Prevalence of PsA and CTT localizations of psoriasis (scalp, nail, and palmoplantar). NP, nail psoriasis; PP, palmoplantar psoriasis; PsA, psoriatic arthritis; SP, scalp psoriasis. Additional mutually exclusive combinations include psoriasis (PsO) with PsA only (n = 427 [20.9%]); PsO with SP only (n = 297 [14.5%]); PsO with NP only (n = 26 [1.3%]); PsO with PP only (n = 58 [2.8%]); PsO with PsA + SP (n = 146 [7.1%]); PsO with PsA + NP (n = 16 [0.8%]); PsO with PsA + PP (n = 27 [1.3%]); PsO with SP and NP (n = 107 [5.2%]); PsO with SP and PP (n = 40 [2.0%]); PsO with NP and PP (n = 6 [0.3%]); PsO with PsA + SP and NP (n = 101 [4.9%]); PsO with PsA + SP and PP (n = 22 [1.1%]); PsO with PsA + NP and PP (n = 5 [0.2%]); PsO with SP, NP, and PP (n = 25 [1.2%]); PsO with PsA + SP, NP, and PP (n = 40 [2.0%]). a Nonmutually exclusive groups.
See this image and copyright information in PMC

References

    1. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol. 2006 Sep-Oct;24((5)):438–47. - PubMed
    1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014 Mar;70((3)):512–6. - PubMed
    1. Feldman SR, Zhao Y, Navaratnam P, Friedman HS, Lu J, Tran MH. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015 Mar;21((3)):201–9. - PMC - PubMed
    1. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6((6)):383–92. - PubMed
    1. Kimball AB, Guérin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011 Feb;25((2)):157–63. - PubMed

Publication types